JP2005535560A - 治療用の化合物 - Google Patents

治療用の化合物 Download PDF

Info

Publication number
JP2005535560A
JP2005535560A JP2003547390A JP2003547390A JP2005535560A JP 2005535560 A JP2005535560 A JP 2005535560A JP 2003547390 A JP2003547390 A JP 2003547390A JP 2003547390 A JP2003547390 A JP 2003547390A JP 2005535560 A JP2005535560 A JP 2005535560A
Authority
JP
Japan
Prior art keywords
compound
tetrahydro
benzazepine
heteroaryl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003547390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005535560A5 (https=
Inventor
ジャン−ミン・フ
Original Assignee
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファルマシア・アンド・アップジョン・カンパニー・エルエルシー filed Critical ファルマシア・アンド・アップジョン・カンパニー・エルエルシー
Publication of JP2005535560A publication Critical patent/JP2005535560A/ja
Publication of JP2005535560A5 publication Critical patent/JP2005535560A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K51/047—Benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2003547390A 2001-11-28 2002-11-26 治療用の化合物 Withdrawn JP2005535560A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33401201P 2001-11-28 2001-11-28
PCT/US2002/037715 WO2003045940A2 (en) 2001-11-28 2002-11-26 Benzazepine derivatives and their use as 5-ht ligands

Publications (2)

Publication Number Publication Date
JP2005535560A true JP2005535560A (ja) 2005-11-24
JP2005535560A5 JP2005535560A5 (https=) 2006-01-19

Family

ID=23305178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003547390A Withdrawn JP2005535560A (ja) 2001-11-28 2002-11-26 治療用の化合物

Country Status (8)

Country Link
US (1) US6861420B2 (https=)
EP (1) EP1451176A2 (https=)
JP (1) JP2005535560A (https=)
AU (1) AU2002346507A1 (https=)
BR (1) BR0214529A (https=)
CA (1) CA2468010A1 (https=)
MX (1) MXPA04005151A (https=)
WO (1) WO2003045940A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04008517A (es) * 2002-03-04 2005-08-19 Pharmacia & Upjohn Co Llc Compuestos terapeuticos.
TW200510324A (en) * 2003-08-11 2005-03-16 Lilly Co Eli 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
CN102329267A (zh) 2004-02-25 2012-01-25 伊莱利利公司 作为5-HT2C受体激动剂的6-取代的2,3,4,5-四氢-1H-苯并［d］氮杂䓬
WO2006117218A2 (en) * 2005-05-04 2006-11-09 Charite Universitätsmedizin - Berlin Serotonin-transport-protein binding radiopharmaceutical for the production of a diagnostic medicament for the diagnosis of headache
EP1728520A1 (de) * 2005-05-04 2006-12-06 Charité - Universitätsmedizin Berlin Verwendung von spezifisch an das Serotonin-Transport-Protein (SERT) bindenden Radiopharmaka zur Herstellung eines Diagnostikums zur Untersuchung von Kopfschmerzerkrankungen
WO2007028082A1 (en) * 2005-09-01 2007-03-08 Eli Lilly And Company 6-substituted- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
JP5249031B2 (ja) * 2005-09-01 2013-07-31 イーライ リリー アンド カンパニー ５−ＨＴ２Ｃ受容体アゴニストとしての６−Ｎ結合型へテロ環置換された２，３，４，５−テトラヒドロ−１Ｈ−ベンゾ［ｄ］アゼピン
WO2007028131A1 (en) 2005-09-01 2007-03-08 Eli Lilly And Company 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
BRPI0615048A2 (pt) 2005-09-01 2010-03-30 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132311A (en) * 1990-06-27 1992-07-21 G. D. Searle & Co. Cyanoquanidine type III antiarrhythmic agents and use
GB9612883D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
GB9612885D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
WO2001095856A2 (en) * 2000-06-15 2001-12-20 Chaconne Nsi Co., Ltd. Urea derivative useful as an anti-cancer agent and process for preparing same

Also Published As

Publication number Publication date
US6861420B2 (en) 2005-03-01
BR0214529A (pt) 2006-05-30
MXPA04005151A (es) 2004-08-11
EP1451176A2 (en) 2004-09-01
AU2002346507A1 (en) 2003-06-10
WO2003045940A2 (en) 2003-06-05
CA2468010A1 (en) 2003-06-05
AU2002346507A8 (en) 2003-06-10
US20030149024A1 (en) 2003-08-07
WO2003045940A3 (en) 2003-09-12

Similar Documents

Publication Publication Date Title
JP2016523923A (ja) Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体
EA018620B1 (ru) ПРОИЗВОДНЫЕ ТИЕНОТРИАЗОЛОДИАЗЕПИНА, АКТИВНЫЕ В ОТНОШЕНИИ Apo A1
TW200902503A (en) New compounds
TW200817406A (en) Imidazole amines as inhibitors of β-secretase
US6930105B2 (en) Tetracyclicazaindoles and indolines having 5-HT activity
JP2001512727A (ja) ５ｈｔ−１受容体のリガンドとしてのニ環式化合物
US7022694B2 (en) Indoles and indolines having 5-HT activity
WO2021202900A1 (en) 1,6-naphthyridine compounds and methods for csk modulation and indications therefor
US6861420B2 (en) N-substituted 1,2,4,5-tetrahydro-1H-benzo[d]azepine compounds
US6762191B2 (en) Therapeutic compounds
US20030087883A1 (en) Therapeutic 5-HT ligand compounds
KR20010102544A (ko) 카르바모일 테트라히드로피리딘 유도체
US7291738B2 (en) Therapeutic compounds
HUT70148A (en) Isoquinolone derivatives as techykinin receptor antagonists, process for producing thereof and pharmaceutical compositions comprising them
ES2226726T3 (es) Tetrahidroquinazolina-2,4-diona y usos terapeuticos de la misma.
EA005071B1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[4,3-e]ДИАЗЕПИНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ИХ, И ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ ПРОДУКТОВ
TW201831462A (zh) 二苯并二氮呯衍生物
BRPI0619955A2 (pt) derivados tricìclicos da lactama, sua produção e seus usos como agentes farmacêuticos
JPH09504789A (ja) ５−ｈｔ１ａレセプターに対して親和性をもつ三環式化合物
ES2364575T3 (es) Derivados de piridina y su uso en el tratamiento de trastornos psicóticos.
JP2002518490A (ja) Ｃｎｓ−疾病の処置のためのｄｆｐ−結合部位の配位子としての新規な２−アミノカルボニル−５（２ｈ）−イソキサゾロン類
AU2002345890A1 (en) (hetero) aryl substituted benzofurans as 5-HT ligands

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051124

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060216